Ian Fletcher Kent

The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

Part of Interfor Corp., Adprotech Ltd. is a British pharmaceutical manufacturing company. The company is based in Royston, UK. Adprotech was acquired by EACOM Timber Corp., part of Interfor Corp. from November 23, 2021 on April 20, 2004 for $15.23 million.

LGC Group Holdings, Ltd. provides pharmaceutical research and laboratory services. It offers chemical analysis and diagnostic services for the public and private sectors. The company was founded in 1996 and is headquartered in Teddington, the United Kingdom.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom.